Neuland Laboratories Ltd: Stock Analysis & Fundamentals

Updated this week

Neuland Laboratories Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 86.4. ROE: 14.8%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

📊Debt increased 69% YoY — leverage rising

🌐FII stake decreased 5.9% this quarter

🏛️DII accumulation — stake up 7.2%

Key Numbers

Current Price

₹12,067

Dividend Yield

0.10%

Market Cap

15.5K Cr

Valuation

N/A

Other Top Pharma - API & CRAMS Stocks Beating Nifty 500

Gland Pharma Ltd

Average

+15.9%

Acutaas Chemicals Ltd

SMS Pharmaceuticals Ltd

Average • 12w streak

+37.7%

← Back to Pharma - API & CRAMS Dashboard

Frequently Asked Questions: Neuland Laboratories Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Neuland Laboratories Ltd's latest quarterly results?

Neuland Laboratories Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: -59.8%
Revenue Growth YoY: +10.6%
Operating Margin: 18.0%

What is Neuland Laboratories Ltd's current PE ratio?

Neuland Laboratories Ltd's current PE ratio is 86.4x.

Current PE: 86.4x
Market Cap: 15.5K Cr
Dividend Yield: 0.10%

What is Neuland Laboratories Ltd's price-to-book ratio?

Neuland Laboratories Ltd's price-to-book ratio is 9.6x.

Price-to-Book (P/B): 9.6x
Book Value per Share: ₹1263
Current Price: ₹12067

Is Neuland Laboratories Ltd a fundamentally strong company?

Neuland Laboratories Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 19.0%

Is Neuland Laboratories Ltd debt free?

Neuland Laboratories Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹265 Cr

What is Neuland Laboratories Ltd's return on equity (ROE) and ROCE?

Neuland Laboratories Ltd's return ratios over recent years

FY2023: ROCE 21.0%
FY2024: ROCE 33.0%
FY2025: ROCE 19.0%

Is Neuland Laboratories Ltd's cash flow positive?

Neuland Laboratories Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹317 Cr
Free Cash Flow (FCF): ₹19 Cr
CFO/PAT Ratio: 122% (strong cash conversion)

What is Neuland Laboratories Ltd's dividend yield?

Neuland Laboratories Ltd's current dividend yield is 0.10%.

Dividend Yield: 0.10%
Current Price: ₹12067

Who holds Neuland Laboratories Ltd shares — promoters, FII, DII?

Neuland Laboratories Ltd's shareholding pattern (Dec 2025)

Promoters: 32.6%
FII (Foreign): 20.9%
DII (Domestic): 14.7%
Public: 31.8%

Is promoter holding increasing or decreasing in Neuland Laboratories Ltd?

Neuland Laboratories Ltd's promoter holding has decreased recently.

Current Promoter Holding: 32.6% (Dec 2025)
Previous Quarter: 32.6% (Sep 2025)
Change: -0.01% (decreasing — worth monitoring)

Is Neuland Laboratories Ltd a new momentum entry or an established outperformer?

Neuland Laboratories Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Neuland Laboratories Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Neuland Laboratories Ltd may be worth studying

Cash flow is positive — CFO ₹317 Cr

What is the investment thesis for Neuland Laboratories Ltd?

Neuland Laboratories Ltd investment thesis summary:

What is the future outlook for Neuland Laboratories Ltd?

Neuland Laboratories Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.